Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension
Mark Toshner, Colin Church, Lars Harbaum, Christopher Rhodes, Sofia S. Villar Moreschi, James Liley, Rowena Jones, Amit Arora, Ken Batai, Ankit A. Desai, John G. Coghlan, J. Simon R. Gibbs, Dee Gor, Stefan Gräf, Louise Harlow, Jules Hernandez-Sanchez, Luke S. Howard, Marc Humbert, Jason Karnes, David G. Kiely, Rick Kittles, Emily Knightbridge, Brian Lam, Katie A. Lutz, William C. Nichols, Michael W. Pauciulo, Joanna Pepke-Zaba, Jay Suntharalingam, Florent Soubrier, Richard C. Trembath, Tae-Hwi L. Schwantes-An, S. John Wort, Martin R. Wilkins, Sean Gaine, Nicholas W. Morrell, Paul A. Corris
Source: Eur Respir J, 59 (3) 2002463; 10.1183/13993003.02463-2020
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Mark Toshner, Colin Church, Lars Harbaum, Christopher Rhodes, Sofia S. Villar Moreschi, James Liley, Rowena Jones, Amit Arora, Ken Batai, Ankit A. Desai, John G. Coghlan, J. Simon R. Gibbs, Dee Gor, Stefan Gräf, Louise Harlow, Jules Hernandez-Sanchez, Luke S. Howard, Marc Humbert, Jason Karnes, David G. Kiely, Rick Kittles, Emily Knightbridge, Brian Lam, Katie A. Lutz, William C. Nichols, Michael W. Pauciulo, Joanna Pepke-Zaba, Jay Suntharalingam, Florent Soubrier, Richard C. Trembath, Tae-Hwi L. Schwantes-An, S. John Wort, Martin R. Wilkins, Sean Gaine, Nicholas W. Morrell, Paul A. Corris. Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. Eur Respir J, 59 (3) 2002463; 10.1183/13993003.02463-2020
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|